Drugs / ACT-389949
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02099201 | Nov 2012 → May 2013 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02099071 | Nov 2011 → May 2012 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACT-389949 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02099201 ↗ |
| Route | Oral | “single oral dose of ACT-389949 1 mg” NCT02099071 ↗ |